FDA Grants Expanded Access Program to Ulixertinib for MAPK Pathway Aberrant Cancer
September 29, 2020

xCures recently announced that the FDA granted its IND immediate Expanded Access Program for the ERK inhibitor ulixertinib to treat patients with MAPK pathway aberrant cancer.

Phase 1 Study of BAY 1895344 Shows Promise in Advanced, Heavily Pre-treated Cancers
September 29, 2020

The ATR inhibitor BAY 1895344 appeared promising in patients with a range of advanced, heavily pre-treated cancers in a dose-escalation portion of a phase 1 clinical trial.

FDA Issues Final Guidance for Certain Labeling Recommendations for Breast Implants
September 29, 2020

The FDA issued the final guidance in order to help improve the information available to patients and health care providers about the risks of breast implants.

NDA Submitted for Prostate Cancer Companion Diagnostic, TLX591-CDx
September 29, 2020

TLX591-CDx (illumet) is a radiopharmaceutical targeting prostate-specific membrane antigen intended for the imaging of prostate cancer using positron emission tomography.

Topical Minoxidil, Procedural Interventions May Benefit Persistent Radiation-Induced Alopecia
September 28, 2020

These study findings suggested that topical minoxidil and procedural interventions may aid in the treatment of persistent radiation-induced alopecia among patients with primary central nervous system tumors or head and neck sarcomas.

Study Highlights Importance of Reporting Data on Multiorgan Toxicities
September 28, 2020

This study found that among clinical trials in which patients with non-small cell lung cancer were treated with atezolizumab, multiorgan immune-related adverse events were reported in 5.4%.